Geron (NASDAQ:GERN) Trading 5.1% Higher - Should You Buy?

Shares of Geron Co. (NASDAQ:GERN - Get Free Report) were up 5.1% on Monday . The company traded as high as $1.37 and last traded at $1.34. Approximately 2,316,338 shares changed hands during mid-day trading, a decline of 80% from the average daily volume of 11,441,197 shares. The stock had previously closed at $1.27.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. Needham & Company LLC reaffirmed a "buy" rating and set a $5.00 price target on shares of Geron in a research note on Wednesday, March 12th. Scotiabank dropped their price target on Geron from $6.00 to $4.00 and set a "sector outperform" rating for the company in a research report on Thursday, February 27th. Barclays restated an "overweight" rating and set a $4.00 price objective (down from $9.00) on shares of Geron in a research report on Thursday, February 27th. B. Riley cut Geron from a "buy" rating to a "neutral" rating and dropped their target price for the stock from $3.50 to $2.00 in a report on Thursday, February 27th. Finally, Stifel Nicolaus decreased their price target on Geron from $8.00 to $4.00 and set a "buy" rating on the stock in a report on Thursday, February 27th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $5.75.

Geron Stock Up 10.2 %

The company's 50 day moving average is $1.76 and its 200 day moving average is $3.01. The company has a market cap of $891.68 million, a PE ratio of -4.38 and a beta of 0.66. The company has a current ratio of 2.89, a quick ratio of 2.74 and a debt-to-equity ratio of 0.04.

Geron (NASDAQ:GERN - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.04). The firm had revenue of $47.54 million during the quarter, compared to analyst estimates of $45.29 million. Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. As a group, analysts predict that Geron Co. will post -0.25 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Geron

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. SBI Securities Co. Ltd. acquired a new position in shares of Geron during the fourth quarter valued at about $28,000. Integrated Wealth Concepts LLC purchased a new stake in Geron during the 4th quarter worth approximately $36,000. Sowell Financial Services LLC acquired a new position in Geron during the 1st quarter valued at approximately $43,000. GF Fund Management CO. LTD. purchased a new position in shares of Geron in the fourth quarter worth $45,000. Finally, 111 Capital acquired a new stake in shares of Geron during the fourth quarter worth $52,000. Hedge funds and other institutional investors own 73.71% of the company's stock.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.